stockrowKymera Therapeutics, Inc.
KYMR Healthcare Biotechnology
Kymera Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $39.2 million, down 16.7% from fiscal 2024.
- Revenue
- +466.4%
- EPS
- −40.3%
- Free cash flow
- −186.6%
- Total debt
- −66.6%
Quarter to September 2026, against a year earlier
Follow KYMR
Alert me
Kymera Therapeutics, Inc. (KYMR) Return on assets
Kymera Therapeutics, Inc.'s return on assets over the twelve months to 30 September 2026 was −24.4%, down 1.5 percentage points from fiscal 2025 (−22.9%). Over the past ten years it has ranged from −97.1% (fiscal 2018) to −18.1% (fiscal 2020); the current reading is higher than 75% of that period. That is above the Biotechnology industry median of −45.6% and above the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | −22.9% | 5.92 |
| FY2024 | −28.8% | (3.88) |
| FY2023 | −24.9% | 0.68 |
| FY2022 | −25.6% | (7.27) |
| FY2021 | −18.3% | (0.24) |
| FY2020 | −18.1% | 33.16 |
| FY2019 | −51.3% | 45.81 |
| FY2018 | −97.1% | — |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| TGTX TG Therapeutics, Inc. compare | 37.7% |
| CAI Caris Life Sciences,�Inc. compare | 8.58% |
| TECH Bio-Techne Corp compare | 7.07% |
| BMRN BioMarin Pharmaceutical Inc. compare | −0.20% |
| TWST Twist Bioscience Corporation compare | −20.8% |
| KYMR Kymera Therapeutics, Inc. | −24.4% |
| PCVX Vaxcyte, Inc. compare | −33.0% |
| SMMT Summit Therapeutics PLC compare | −159.1% |
| IBRX ImmunityBio, Inc. compare | −192.6% |
| Biotechnology industry median | −45.6% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on KYMR
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement